BioSpace News Archive

NuVasive, Inc. (NASDAQ: NUVA), today announced the resignation of Massimo Calafiore, executive vice president and chief commercial officer, effective August 31, 2022, to become the chief executive officer of a privately-held, orthopedics technology company.

The National Institute for Innovation in Manufacturing Biopharmaceuticals is pleased to announce approximately $15.8M in planned project activities through the Institute’s Project Call 5.2 for 14 new projects in technology and workforce development that will help to address key opportunities for innovation in the biopharmaceutical industry.

BioMarker Strategies announced that the journal CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS has published a manuscript by the Company’s scientists entitled “Functional Profiling of Head and Neck/Esophageal Squamous Cell Carcinoma to Predict Cetuximab Response”.

eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2022, and provided a corporate update.

Metacrine, Inc., a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, reported its second-quarter 2022 financial results.

Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a woman’s health company focused on the treatment of Abnormal Uterine Bleeding (AUB), today reported second quarter financial results for the period ended June 30, 2022.

Vaccitech plc (NASDAQ: VACC) today announced its financial results for the second quarter ended June 30, 2022 and provided an overview of the Company’s recent corporate developments.

CooperCompanies announced that Nicholas Khadder has been appointed as its general counsel and corporate secretary.

Aethlon Medical, Inc., a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, reported financial results for its first quarter ended June 30, 2022 and provided an update on recent developments.

Total revenue of $46 million, compared to $28 million in Q2 2021 Four program starts in the quarter bringing cumulative total to 88, up 47% from Q2 2021 Net loss of per share on a basic and diluted basis compared to per share in Q2 2021